Pfizer To Buy RSV Drug Developer ReViral For Up To $525 Million

Reuters2022-04-07

(Reuters) -Pfizer Inc said on Thursday it would buy privately-held ReViral Ltd in a deal worth as much as $525 million, including milestone payments, to gain access to experimental drugs against the respiratory syncytial virus (RSV).

London-based Reviral has four RSV therapies in its pipeline, with two currently in mid-stage studies, including its lead product candidate sisunatovir.

The deal marks the U.S. drugmaker's second acquisition in less than six months to enhance its drug portfolio. Pfizer acquired Arena Pharmaceuticals in a deal worth $6.7 billion in December, adding a promising bowel disease treatment to its ranks.

RSV is a common respiratory virus that causes symptoms similar to those of a cold. It is a common cause of pneumonia in toddlers and the elderly.

According to analytics firm GlobalData, the RSV prevention market is expected to grow fourteen-fold to $6.3 bln by 2030 from 2020, making it a lucrative market for drugmakers globally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Calvin_GKH
2022-04-08
Calvin_GKH
Wow
wniewnie
2022-04-07
wniewnie
Nice
Tanyl
2022-04-07
Tanyl
PFE is a good choice to invest
dahae
2022-04-07
dahae
A
ValuInvestor
2022-04-07
ValuInvestor
Ok
JL1978
2022-04-07
JL1978
Buy buy buy!

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2225459005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-04-07 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2225459005","market":"us","top_or_hot":-1,"title":"Pfizer To Buy RSV Drug Developer ReViral For Up To $525 Million","media":"Reuters","content":"<html><head></head><body><p>(Reuters) -<a href=\"https://laohu8.com/S/PFE\">Pfizer Inc</a> said on Thursday it would buy privately-held ReViral Ltd in a deal worth as much as $525 million, including milestone payments, to gain access to experimental drugs against the respiratory syncytial virus (RSV).</p><p>London-based Reviral has four RSV therapies in its pipeline, with two currently in mid-stage studies, including its lead product candidate sisunatovir.</p><p>The deal marks the U.S. drugmaker&#39;s second acquisition in less than six months to enhance its drug portfolio. Pfizer acquired Arena Pharmaceuticals in a deal worth $6.7 billion in December, adding a promising bowel disease treatment to its ranks.</p><p>RSV is a common respiratory virus that causes symptoms similar to those of a cold. It is a common cause of pneumonia in toddlers and the elderly.</p><p>According to analytics firm GlobalData, the RSV prevention market is expected to grow fourteen-fold to $6.3 bln by 2030 from 2020, making it a lucrative market for drugmakers globally.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer To Buy RSV Drug Developer ReViral For Up To $525 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer To Buy RSV Drug Developer ReViral For Up To $525 Million\n</h2>\n\n<h4 class=\"meta\">\n\n2022-04-07 19:31 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Pfizer Inc said on Thursday it would buy privately-held ReViral Ltd in a deal worth as much as $525 million, including milestone payments, to gain access to experimental drugs against the ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"2225459005","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2225459005","pubTimestamp":1649331084,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"(Reuters) -Pfizer Inc said on Thursday it would buy privately-held ReViral Ltd in a deal worth as mu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4581":"高盛持仓","BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓","PFE":"辉瑞","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"辉瑞将以高达5.25亿美元的价格收购RSV药物开发商ReViral","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"(Reuters) -Pfizer Inc said on Thursday it would buy privately-held ReViral Ltd in a deal worth as much as $525 million, including milestone payments, to gain access to experimental drugs against the respiratory syncytial virus (RSV).London-based Reviral has four RSV therapies in its pipeline, with two currently in mid-stage studies, including its lead product candidate sisunatovir.The deal marks the U.S. drugmaker's second acquisition in less than six months to enhance its drug portfolio. Pfizer acquired Arena Pharmaceuticals in a deal worth $6.7 billion in December, adding a promising bowel disease treatment to its ranks.RSV is a common respiratory virus that causes symptoms similar to those of a cold. It is a common cause of pneumonia in toddlers and the elderly.According to analytics firm GlobalData, the RSV prevention market is expected to grow fourteen-fold to $6.3 bln by 2030 from 2020, making it a lucrative market for drugmakers globally.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9012405494,"gmtCreate":1649372565646,"gmtModify":1676534498721,"author":{"id":"3583232588242926","authorId":"3583232588242926","name":"Calvin_GKH","avatar":"https://static.tigerbbs.com/562335042bbb987f5b9370e6664fc2dc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583232588242926","authorIdStr":"3583232588242926"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012405494","repostId":2225459005,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012249269,"gmtCreate":1649343446631,"gmtModify":1676534495164,"author":{"id":"4095228411424310","authorId":"4095228411424310","name":"wniewnie","avatar":"https://community-static.tradeup.com/news/25dcbc454266cc0710cc81103ccaa391","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4095228411424310","authorIdStr":"4095228411424310"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012249269","repostId":2225459005,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012266541,"gmtCreate":1649340955627,"gmtModify":1676534494559,"author":{"id":"4087109808120260","authorId":"4087109808120260","name":"Tanyl","avatar":"https://static.tigerbbs.com/174329973340cf0f5b68791ee5b08afd","vip":1,"crmLevel":9,"crmLevelSwitch":1,"idStr":"4087109808120260","authorIdStr":"4087109808120260"},"htmlText":"PFE is a good choice to invest","listText":"PFE is a good choice to invest","text":"PFE is a good choice to invest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012266541","repostId":2225459005,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012214736,"gmtCreate":1649339411204,"gmtModify":1676534494078,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012214736","repostId":2225459005,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012235516,"gmtCreate":1649338444970,"gmtModify":1676534493746,"author":{"id":"4087361572396550","authorId":"4087361572396550","name":"ValuInvestor","avatar":"https://static.tigerbbs.com/5a962911d3cd0763a9f0cb01392cacd9","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087361572396550","authorIdStr":"4087361572396550"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012235516","repostId":2225459005,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012299524,"gmtCreate":1649336193873,"gmtModify":1676534493411,"author":{"id":"4090484578937160","authorId":"4090484578937160","name":"JL1978","avatar":"https://static.tigerbbs.com/31c2270189444544a4667875199da31f","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4090484578937160","authorIdStr":"4090484578937160"},"htmlText":"Buy buy buy!","listText":"Buy buy buy!","text":"Buy buy buy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012299524","repostId":2225459005,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":94,"commentSize":13,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2225459005"}